Get the Stockscreener App
1.47
5.77%
-0.09
Pre-market:
1.49
0.02
+1.36%
Pacific Biosciences of California Inc stock is currently priced at $1.47, with a 24-hour trading volume of 9.72M.
It has seen a -5.77% decreased in the last 24 hours and a -60.05% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.54 pivot point. If it approaches the $1.41 support level, significant changes may occur.
Previous Close:
$1.56
Open:
$1.56
24h Volume:
9.72M
Market Cap:
$393.89M
Revenue:
$200.52M
Net Income/Loss:
$-306.74M
P/E Ratio:
-1.1575
EPS:
-1.27
Net Cash Flow:
$-268.02M
1W Performance:
+5.00%
1M Performance:
-60.05%
6M Performance:
-79.75%
1Y Performance:
-86.65%
1D Range:
$1.45
$1.65
52W Range:
$1.25
$14.55
Pacific Biosciences of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'Brien Drive, Menlo Park, CA
Pacific Biosciences of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences of California Inc Stock (PACB) Latest News
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
A Glimpse Into The Expert Outlook On Pacific Biosciences Through 4 Analysts
Benzinga
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
Zacks Investment Research
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
Benzinga
S&P 500 Edges Lower; PacBio Shares Plunge
Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Pacific Biosciences of California Inc Stock (PACB) Financials Data
Pacific Biosciences of California Inc (PACB) Revenue 2024
PACB reported a revenue (TTM) of $200.52 million for the quarter ending December 31, 2023, a +56.29% rise year-over-year.
Pacific Biosciences of California Inc (PACB) Net Income 2024
PACB net income (TTM) was -$306.74 million for the quarter ending December 31, 2023, a +2.39% increase year-over-year.
Pacific Biosciences of California Inc (PACB) Cash Flow 2024
PACB recorded a free cash flow (TTM) of -$268.02 million for the quarter ending December 31, 2023, a +4.33% increase year-over-year.
Pacific Biosciences of California Inc (PACB) Earnings per Share 2024
PACB earnings per share (TTM) was -$1.21 for the quarter ending December 31, 2023, a +13.57% growth year-over-year.
Pacific Biosciences of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORDONEZ KATHY | Director |
Mar 15 '24 |
Option Exercise |
2.87 |
361,621 |
1,038,682 |
380,216 |
| Meline David W | Director |
Mar 06 '24 |
Buy |
4.40 |
40,000 |
176,160 |
40,000 |
| HENRY CHRISTIAN O | See Remarks |
Mar 04 '24 |
Sale |
4.87 |
14,177 |
69,056 |
2,596,670 |
| Van Oene Mark | See Remarks |
Mar 04 '24 |
Sale |
4.87 |
9,186 |
44,745 |
1,668,826 |
| Kim Susan G. | See Remarks |
Mar 04 '24 |
Sale |
4.87 |
5,275 |
25,695 |
712,260 |
| Farmer Michele | See Remarks |
Mar 04 '24 |
Sale |
4.87 |
2,968 |
14,457 |
217,216 |
| MOHR MARSHALL | Director |
Mar 01 '24 |
Option Exercise |
4.45 |
25,000 |
111,250 |
110,000 |
| HENRY CHRISTIAN O | See Remarks |
Feb 20 '24 |
Sale |
5.26 |
1,979 |
10,412 |
1,005,078 |
| Kim Susan G. | See Remarks |
Feb 20 '24 |
Sale |
5.26 |
831 |
4,372 |
282,758 |
| HENRY CHRISTIAN O | See Remarks |
Feb 16 '24 |
Sale |
5.96 |
79,038 |
470,908 |
1,007,057 |
About Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
1.94%
Cap:
|
Volume (24h):